Auna S.A. Q4 FY2025 earnings call

• Mexico: Stabilized operations, new management team implemented actions, included in preferred provider tiers, rollout of package services, out-of-pocket segment reached 12% of revenues. - Peru: Outperforms in revenue and EBITDA, revenue driven by growth in high complexity services, OncoSalud revenues grew 10%. - Colombia: Constrained services to government intervened payers, expanded risk-sharing models, revenue grew 6% q-o-q.

Mexico: Fourth quarter oncology revenues grew 35% q-o-q, local currency revenues declined 3%, adjusted EBITDA declined 36%; full year local currency revenues declined 3%, adjusted EBITDA declined 18%. Peru: Quarter revenue grew 11%, adjusted EBITDA grew 14%; full year revenue grew 4%, adjusted EBITDA declined 3%. Colombia: Quarter revenue grew 6%, adjusted EBITDA affected by risk sharing contracts etc.

Expect adjusted EBITDA to increase 12% FX neutral, revenue growth of 12%, CapEx to remain at approximately 4% of revenue

Market conditions in Mexico, issues with physicians/suppliers/info systems in Mexico, results of key initiatives in regions, capacity and market of Torre Treka, execution of strategic plan

Q: Explore guidance breakdown by region and business line, margin expectations, risks to guidance.

A: Mexico off to solid start, margins to improve in 2026, guidance achievable with volume growth, macro conditions, payer dynamics.

Q: Detail Torre Treca project, financing, operating.

A: Structured under concession, reimbursed by progress certificates, reduces capital risk, commences operation in second semester of 2028, represents significant business for AUNA